Diagonal Bio (DIABIO) Q3 2025 earnings summary

Executive summary

• Achieved key commercial milestone with Stall Courant's order of LAMPlify and a 36-month leasing agreement, expanding presence in the equine diagnostics market.

• Launched a new test for Equine Herpesvirus type 2 (EHV-2), broadening the product portfolio for equine health.

• Filed a Swedish patent application for a computational method improving LAMP primer design, and received a Japanese patent grant for a proprietary detection method.

• Initiated collaboration with the Swedish Veterinary Agency to evaluate equine coronavirus testing, supporting scientific validation and market expansion.

• Launched a new website to strengthen commercial presence and focus on the animal health market.

Financial highlights

• Net sales for Q3 2025 were 45 KSEK, up from 0 KSEK in Q3 2024.

• Net loss after financial items was -2,042 KSEK, compared to -1,242 KSEK in the same quarter last year.

• Cash flow for the quarter was -1,002 KSEK, an improvement from -2,428 KSEK in Q3 2024.

• Cash and cash equivalents at period end were 1,737 KSEK, nearly unchanged from 1,730 KSEK a year earlier.

• Investments in intangible assets (patents and trademarks) totaled 108 KSEK, and capitalized development expenses were 238 KSEK.

Outlook and guidance

• Focus remains on expanding LAMPlify's market presence and leveraging the growing IP portfolio for long-term value.

• Ongoing collaborations and new product launches are expected to drive further commercial and scientific progress.